AAPL   382.73 (+0.36%)
MSFT   214.32 (+0.70%)
FB   244.50 (+0.38%)
GOOGL   1,518.66 (+1.00%)
AMZN   3,182.63 (+3.29%)
NVDA   420.36 (+2.87%)
CGC   16.02 (-1.90%)
BABA   261.58 (+1.51%)
MU   49.98 (+0.54%)
GE   6.58 (-4.08%)
TSLA   1,394.28 (+2.08%)
AMD   57.26 (+7.17%)
T   29.54 (-3.02%)
ACB   11.77 (-3.21%)
F   5.84 (-4.11%)
GILD   74.71 (-1.19%)
DIS   116.81 (+0.13%)
BAC   22.77 (-1.43%)
NFLX   507.76 (+0.99%)
BA   173.28 (-3.78%)
AAPL   382.73 (+0.36%)
MSFT   214.32 (+0.70%)
FB   244.50 (+0.38%)
GOOGL   1,518.66 (+1.00%)
AMZN   3,182.63 (+3.29%)
NVDA   420.36 (+2.87%)
CGC   16.02 (-1.90%)
BABA   261.58 (+1.51%)
MU   49.98 (+0.54%)
GE   6.58 (-4.08%)
TSLA   1,394.28 (+2.08%)
AMD   57.26 (+7.17%)
T   29.54 (-3.02%)
ACB   11.77 (-3.21%)
F   5.84 (-4.11%)
GILD   74.71 (-1.19%)
DIS   116.81 (+0.13%)
BAC   22.77 (-1.43%)
NFLX   507.76 (+0.99%)
BA   173.28 (-3.78%)
AAPL   382.73 (+0.36%)
MSFT   214.32 (+0.70%)
FB   244.50 (+0.38%)
GOOGL   1,518.66 (+1.00%)
AMZN   3,182.63 (+3.29%)
NVDA   420.36 (+2.87%)
CGC   16.02 (-1.90%)
BABA   261.58 (+1.51%)
MU   49.98 (+0.54%)
GE   6.58 (-4.08%)
TSLA   1,394.28 (+2.08%)
AMD   57.26 (+7.17%)
T   29.54 (-3.02%)
ACB   11.77 (-3.21%)
F   5.84 (-4.11%)
GILD   74.71 (-1.19%)
DIS   116.81 (+0.13%)
BAC   22.77 (-1.43%)
NFLX   507.76 (+0.99%)
BA   173.28 (-3.78%)
AAPL   382.73 (+0.36%)
MSFT   214.32 (+0.70%)
FB   244.50 (+0.38%)
GOOGL   1,518.66 (+1.00%)
AMZN   3,182.63 (+3.29%)
NVDA   420.36 (+2.87%)
CGC   16.02 (-1.90%)
BABA   261.58 (+1.51%)
MU   49.98 (+0.54%)
GE   6.58 (-4.08%)
TSLA   1,394.28 (+2.08%)
AMD   57.26 (+7.17%)
T   29.54 (-3.02%)
ACB   11.77 (-3.21%)
F   5.84 (-4.11%)
GILD   74.71 (-1.19%)
DIS   116.81 (+0.13%)
BAC   22.77 (-1.43%)
NFLX   507.76 (+0.99%)
BA   173.28 (-3.78%)
Log in

NASDAQ:KZIAKazia Therapeutics Stock Price, Forecast & News

$3.67
-0.13 (-3.42 %)
(As of 07/9/2020 04:00 PM ET)
Add
Compare
Today's Range
$3.60
Now: $3.67
$3.84
50-Day Range
$2.62
MA: $3.12
$3.60
52-Week Range
$2.27
Now: $3.67
$9.74
Volume9,993 shs
Average Volume35,080 shs
Market Capitalization$26.49 million
P/E RatioN/A
Dividend YieldN/A
Beta1.75
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops therapies for a range of oncology indications. Its lead product is GDC-0084, a small molecule inhibitor of the PI3K / AKT / mTOR pathway that is in Phase II clinical trials to treat glioblastoma multiforme. The company is also developing TRX-E-002-1 (Cantrixil), a third-generation benzopyran molecule, which is in Phase I clinical trials to treat ovarian cancer. It has collaboration agreements with The University of York, The Children's Cancer Institute Australia, The Mater Institute in Queensland, the University of Boston, and St Jude Children's Research Hospital, as well as Dana-Farber Cancer Institute. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was founded in 1994 and is based in Sydney, Australia.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 1.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.38 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:KZIA
CUSIPN/A
CIKN/A
Phone61-2-9472-4101

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.12 million
Book Value$1.63 per share

Profitability

Miscellaneous

EmployeesN/A
Market Cap$26.49 million
Next Earnings Date9/3/2020 (Estimated)
OptionableNot Optionable

Receive KZIA News and Ratings via Email

Sign-up to receive the latest news and ratings for KZIA and its competitors with MarketBeat's FREE daily newsletter.

Kazia Therapeutics (NASDAQ:KZIA) Frequently Asked Questions

How has Kazia Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Kazia Therapeutics' stock was trading at $3.98 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, KZIA shares have decreased by 7.8% and is now trading at $3.67. View which stocks have been most impacted by Coronavirus.

When is Kazia Therapeutics' next earnings date?

Kazia Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, September 3rd 2020. View our earnings forecast for Kazia Therapeutics.

Has Kazia Therapeutics been receiving favorable news coverage?

News headlines about KZIA stock have been trending somewhat negative recently, according to InfoTrie. The research firm ranks the sentiment of press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Kazia Therapeutics earned a media sentiment score of -1.6 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the immediate future. View the latest news about Kazia Therapeutics.

Who are some of Kazia Therapeutics' key competitors?

What other stocks do shareholders of Kazia Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kazia Therapeutics investors own include AbbVie (ABBV), Corbus Pharmaceuticals (CRBP), General Motors (GM), Pembina Pipeline (PBA), Abeona Therapeutics (ABEO), Acer Therapeutics (ACER), Achillion Pharmaceuticals (ACHN), Acasti Pharma (ACST), Adamis Pharmaceuticals (ADMP) and Advaxis (ADXS).

Who are Kazia Therapeutics' key executives?

Kazia Therapeutics' management team includes the following people:
  • Dr. James Garner M.A.I.C.D., M.B.A., B.Sc., M.A., MBA, MBBS, B.Sc (, CEO, MD & Exec. Director (Age 46)
  • Ms. Gabrielle Heaton, Director of Fin. & Admin.
  • Ms. Catherine Jane Hill, Company Sec. (Age 60)
  • Kym Robins, Director of Marketing & Communications
  • Dr. Justine R. Stehn B.Sc (Hons), Ph.D., Director of ATM Program

What is Kazia Therapeutics' stock symbol?

Kazia Therapeutics trades on the NASDAQ under the ticker symbol "KZIA."

How do I buy shares of Kazia Therapeutics?

Shares of KZIA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Kazia Therapeutics' stock price today?

One share of KZIA stock can currently be purchased for approximately $3.67.

How big of a company is Kazia Therapeutics?

Kazia Therapeutics has a market capitalization of $26.49 million and generates $1.12 million in revenue each year. The company earns $-7,340,000.00 in net income (profit) each year or ($1.25) on an earnings per share basis.

What is Kazia Therapeutics' official website?

The official website for Kazia Therapeutics is www.kaziatherapeutics.com.

How can I contact Kazia Therapeutics?

Kazia Therapeutics' mailing address is Three International Towers Level 24 300 Barangaroo Avenue, Sydney C3, 2000. The company can be reached via phone at 61-2-9472-4101 or via email at [email protected]

This page was last updated on 7/9/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.